How does one live with psoriasis? From medication to nutrition (and beyond), Olivia Marks goes in search of clear answers.

Despite the classic presentation described above, the morphology can range from small tear shaped papules (guttate psoriasis ... s life that determine “treatment success”. For a clinically meaningful ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The treatment is a monoclonal antibody targeting IL-17A and IL-17F, potentially offering less frequent dosing for psoriasis patients. With a market capitalization of $398 million, Oruka maintains ...